Drug Discovery · Boston, MA · Founded 2022 · Privately Held (backing)
Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development. Superluminal Medicines is based in Boston, MA and was founded in 2022. It was valued at $576 million at its Series B in Sep 2026, the last priced event on record. It has raised $158 million across 4 recorded rounds; the latest was a $65.5 million Series B in Sep 2026.
PMV mark · valuation
$576.3M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$157.7M
Last round
Series B
Sep 2026
No prints on record
No secondary trades in Superluminal Medicines shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Superluminal Medicines with a free account
·The post-money valuation on its round
·The complete investor list: 12 names
·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Superluminal Medicines stock.
